IE
ABVX

Israel Englander’s Abivax ABVX Stock Holding History

Israel Englander’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.85M Buy
73,900
+58,800
+389% +$6.65M ﹤0.01% 2292
2026
Q1 		$1.68M Buy
+15,100
New +$1.79M ﹤0.01% 4023

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Israel Englander's ABVX Position: Q2 2026 in Review

Israel Englander reduced its Abivax (ABVX) stake by 61% in Q2 2026, selling an estimated $42.1M and leaving 233,740 shares worth $31.1M. The position accounts for 0.01% of the portfolio, ranked #1242.

Israel Englander first reported a position in ABVX in Q4 2023 and has held it in 11 quarters since. The position peaked at $99.9M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Israel Englander held 233,740 shares of Abivax worth $31.1M as of Q2 2026.
  • Israel Englander sold 372,252 Abivax shares in Q2 2026, an estimated $42.1M.
  • Abivax made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1242 holding.
  • Israel Englander first reported a position in Abivax in Q4 2023 and has held it in 11 quarters since.
  • Israel Englander's Abivax position peaked at $99.9M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.